DB
BNTC icon

Dmitry Balyasny’s Benitec Biopharma BNTC Stock Holding History

Dmitry Balyasny’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.7M Sell
650,503
-3,332
-0.5% -$39.5K 0.01% 1107
2026
Q1 		$6.96M Buy
653,835
+2,277
+0.3% +$26.4K 0.01% 1207
2025
Q4 		$8.78M Buy
+651,558
New +$9.01M 0.01% 1090
2025
Q2 		– Sell
-2,816
Closed -$39.4K – 2846
2025
Q1 		$36.6K Buy
+2,816
New +$34.1K ﹤0.01% 2714

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Dmitry Balyasny's BNTC Position: Q2 2026 in Review

Dmitry Balyasny reduced its Benitec Biopharma (BNTC) stake by 0.51% in Q2 2026, selling an estimated $39.5K and leaving 650,503 shares worth $8.7M. The position accounts for 0.01% of the portfolio, ranked #1107.

Dmitry Balyasny first reported a position in BNTC in Q1 2025 and has held it in 4 quarters since. The position peaked at $8.78M in Q4 2025. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Dmitry Balyasny held 650,503 shares of Benitec Biopharma worth $8.7M as of Q2 2026.
  • Dmitry Balyasny sold 3,332 Benitec Biopharma shares in Q2 2026, an estimated $39.5K.
  • Benitec Biopharma made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1107 holding.
  • Dmitry Balyasny first reported a position in Benitec Biopharma in Q1 2025 and has held it in 4 quarters since.
  • Dmitry Balyasny's Benitec Biopharma position peaked at $8.78M in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.